Dose-confirmatory Bridging Study in Total Hip Replacement

Inclusion Criteria: * Male and female patients aged 20 years or above * Patients undergoing elective THR (the first replacement of the applicable hip joint) * Patients' written informed consent to participation after receiving detailed verbal and written information on any study specific procedures in advance Exclusion Criteria: * Planned, staged major orthopedic surgery within 3 months prior to elective THR or during this study * History of clinically significant active bleeding (e.g. intracranial bleeding, gastrointestinal bleeding\*), or high bleeding risk \*: within 3 months prior to elective THR for gastrointestinal bleeding * Subjects with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk * Severe impaired renal function (CLCR calculated by Cockcroft-Gault formula: \<30 mL/min) * Conditions prohibiting bilateral venography (e.g. amputation of 1 leg, allergy to contrast media) * Ongoing anticoagulant therapy (e.g. warfarin, heparins and Factor Xa inhibitors other than study medication) that cannot be stopped (in the opinion of the investigator/sub investigator) * Subjects for whom epidural catheters are expected to be left in for longer than 18 hours post-operatively * Planned intermittent pneumatic compression during treatment period